163 related articles for article (PubMed ID: 23967446)
1. [The most important aspects of risk assessment].
Wilhelm TJ; Post S
Zentralbl Chir; 2013 Jun; 138(3):219-21. PubMed ID: 23967446
[No Abstract] [Full Text] [Related]
2. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Otterstad JE; Brosstad F
Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
[No Abstract] [Full Text] [Related]
3. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
4. [New antiaggregants and their importance for the practitioner].
Tsakiris DA
Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
[TBL] [Abstract][Full Text] [Related]
5. The use of antiplatelet agents in acute cardiac care.
Calvin JE; Klein LW
Crit Care Clin; 2001 Apr; 17(2):365-77, vii. PubMed ID: 11450321
[TBL] [Abstract][Full Text] [Related]
6. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
7. [Reduction of haemorrhagic risk in acute coronary syndromes].
Merino A; Roldán I; Marín F; Worner F;
Med Clin (Barc); 2011 Nov; 137(14):650-5. PubMed ID: 20701931
[No Abstract] [Full Text] [Related]
8. The role of platelets in peripheral arterial disease: therapeutic implications.
Matsagas MI; Geroulakos G; Mikhailidis DP
Ann Vasc Surg; 2002 Mar; 16(2):246-58. PubMed ID: 11972262
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet agents and arterial thrombosis.
Billett HH
Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
[TBL] [Abstract][Full Text] [Related]
10. Platelet function testing in cardiovascular diseases.
Michelson AD
Circulation; 2004 Nov; 110(19):e489-93. PubMed ID: 15533872
[No Abstract] [Full Text] [Related]
11. [Recommendations for peri-procedural thrombocyte aggregation inhibition].
Sauer H; Leschke M
Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474
[No Abstract] [Full Text] [Related]
12. Clopidogrel for the prevention of atherothrombotic events.
Kamalesh M
N Engl J Med; 2006 Jul; 355(4):420; author reply 420-1. PubMed ID: 16874904
[No Abstract] [Full Text] [Related]
13. [New antiplatelet agents].
Beer JH
Praxis (Bern 1994); 1999 May; 88(19):853-60. PubMed ID: 10409883
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel resistance?
Gurbel PA; Tantry US
Thromb Res; 2007; 120(3):311-21. PubMed ID: 17109936
[TBL] [Abstract][Full Text] [Related]
15. Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Ann Intern Med; 2005 Feb; 142(4):I53. PubMed ID: 15710954
[No Abstract] [Full Text] [Related]
16. Clopidogrel plus aspirin in atrial fibrillation.
Goldstein LB
N Engl J Med; 2009 Sep; 361(13):1313; author reply 1314-5. PubMed ID: 19780217
[No Abstract] [Full Text] [Related]
17. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
Xhelili E; Eichelberger B; Kopp CW; Koppensteiner R; Panzer S; Gremmel T
Angiology; 2016 Nov; 67(10):902-908. PubMed ID: 26861857
[TBL] [Abstract][Full Text] [Related]
18. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Denardo SJ; Davis KE; Tcheng JE
Am Heart J; 2005 Jan; 149(1):138-44. PubMed ID: 15660045
[TBL] [Abstract][Full Text] [Related]
19. Novel platelet inhibitors.
Bennett JS
Annu Rev Med; 2001; 52():161-84. PubMed ID: 11160773
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Meinertz T
Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
